Geron welcomes Dawn Bir and Elizabeth O’Farrell to its Board as Independent Directors

– USA, CA –  Geron Corporation (Nasdaq:GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its Board of Directors.

In addition, Ms. Bir will serve as a member of the Board’s Nominating and Corporate Governance Committee, and Ms. O’Farrell will serve as a member of the Board’s Audit Committee.

“We enthusiastically welcome two accomplished biopharmaceutical executives to Geron’s Board, both of whom have deep experience with guiding the growth of companies from clinical to commercial stage,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “We believe their contributions will be invaluable as we advance our lead indication for imetelstat in lower risk MDS to Phase 3 clinical development and, in the future, begin preparations for the potential commercialization of imetelstat.”

About Dawn Bir

Dawn C. Bir currently serves as the Chief Commercial Officer of Reata Pharmaceuticals, where she leads marketing, market access, sales and commercial operations. Prior to Reata, Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie Company, where she built and led their first hematology national sales organization responsible for the launch of IMBRUVICA, a hematology-oncology product, in the United States and Puerto Rico. Ms. Bir has also held sales and marketing roles at SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within McKesson Corporation; Genentech, a member of the Roche Group; and Bristol-Myers Squibb Company. Ms. Bir holds a B.S. in Biology from Binghamton University in Binghamton, New York.

About Elizabeth O’Farrell

Elizabeth G. O’Farrell most recently served as Chief Procurement Officer and Head of Global Shared Services at Eli Lilly and Company. Throughout her 24-year career with Eli Lilly, she held several senior management positions in finance and corporate governance, including: Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O’Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company and Price Waterhouse. Ms. O’Farrell currently serves as a member of the board of directors of PDL BioPharma, Inc. and on the finance committee of the United Way of Brevard in Brevard County, Florida. Ms. O’Farrell holds a B.S. in accounting and an M.B.A. in management information systems, both from Indiana University in Bloomington, Indiana.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>